RPMI 1640 Medium was developed at Roswell Park Memorial Institute in 1966 by Moore and his co-workers. A modification of McCoy's 5A Medium, it was formulated to support lymphoblastoid cells in suspension culture, but it has since been shown to support a wide variety of cells that are anchorage dependent. Originally intended to be used with a serum supplement, RPMI 1640 has been shown to support several cell lines in the absence of serum. It has also been widely used in fusion protocols and in the growth of hybrid cells.
RPMI 1640 Medium was developed at Roswell Park Memorial Institute in 1966 by Moore and his co-workers. A modification of McCoy's 5A Medium, it was formulated to support lymphoblastoid cells in suspension culture, but it has since been shown to support a wide variety of cells that are anchorage dependent. Originally intended to be used with a serum supplement, RPMI 1640 has been shown to support several cell lines in the absence of serum. It has also been widely used in fusion protocols and in the growth of hybrid cells.
RPMI 1640 Medium was developed at Roswell Park Memorial Institute in 1966 by Moore and his co-workers. A modification of McCoy's 5A Medium, it was formulated to support lymphoblastoid cells in suspension culture, but it has since been shown to support a wide variety of cells that are anchorage dependent. Originally intended to be used with a serum supplement, RPMI 1640 has been shown to support several cell lines in the absence of serum. It has also been widely used in fusion protocols and in the growth of hybrid cells.
RPMI 1640 Medium was developed at Roswell Park Memorial Institute in 1966 by Moore and his co-workers. A modification of McCoy's 5A Medium, it was formulated to support lymphoblastoid cells in suspension culture, but it has since been shown to support a wide variety of cells that are anchorage dependent. Originally intended to be used with a serum supplement, RPMI 1640 has been shown to support several cell lines in the absence of serum. It has also been widely used in fusion protocols and in the growth of hybrid cells.
RPMI 1640 Medium was developed at Roswell Park Memorial Institute in 1966 by Moore and his co-workers. A modification of McCoy's 5A Medium, it was formulated to support lymphoblastoid cells in suspension culture, but it has since been shown to support a wide variety of cells that are anchorage dependent. Originally intended to be used with a serum supplement, RPMI 1640 has been shown to support several cell lines in the absence of serum. It has also been widely used in fusion protocols and in the growth of hybrid cells.
RPMI 1640 Medium was developed at Roswell Park Memorial Institute in 1966 by Moore and his co-workers. A modification of McCoy's 5A Medium, it was formulated to support lymphoblastoid cells in suspension culture, but it has since been shown to support a wide variety of cells that are anchorage dependent. Originally intended to be used with a serum supplement, RPMI 1640 has been shown to support several cell lines in the absence of serum. It has also been widely used in fusion protocols and in the growth of hybrid cells.
RPMI 1640 Medium was developed at Roswell Park Memorial Institute in 1966 by Moore and his co-workers. A modification of McCoy's 5A Medium, it was formulated to support lymphoblastoid cells in suspension culture, but it has since been shown to support a wide variety of cells that are anchorage dependent. Originally intended to be used with a serum supplement, RPMI 1640 has been shown to support several cell lines in the absence of serum. It has also been widely used in fusion protocols and in the growth of hybrid cells.
RPMI 1640 Medium was developed at Roswell Park Memorial Institute in 1966 by Moore and his co-workers. A modification of McCoy's 5A Medium, it was formulated to support lymphoblastoid cells in suspension culture, but it has since been shown to support a wide variety of cells that are anchorage dependent. Originally intended to be used with a serum supplement, RPMI 1640 has been shown to support several cell lines in the absence of serum. It has also been widely used in fusion protocols and in the growth of hybrid cells.
RPMI 1640 Medium was developed at Roswell Park Memorial Institute in 1966 by Moore and his co-workers. A modification of McCoy's 5A Medium, it was formulated to support lymphoblastoid cells in suspension culture, but it has since been shown to support a wide variety of cells that are anchorage dependent. Originally intended to be used with a serum supplement, RPMI 1640 has been shown to support several cell lines in the absence of serum. It has also been widely used in fusion protocols and in the growth of hybrid cells.
RPMI 1640 培养基由 Moore 及其同事于 1966 年在 Roswell Park Memorial Institute 开发。它是 McCoy′s 5A 培养基的改良型，在悬浮培养中可支持淋巴母细胞样细胞，但也证实可支持众多锚定依赖性细胞。最初设计为需要补充血清，但在无血清条件下，RPMI 1640 也表现出可支持多种细胞系的生长。它还广泛用于细胞融合和杂交细胞的生长。
RPMI 1640 培养基由 Moore 及其同事于 1966 年在 Roswell Park Memorial Institute 开发。它是 McCoy′s 5A 培养基的改良型，在悬浮培养中可支持淋巴母细胞样细胞，但也证实可支持众多锚定依赖性细胞。最初设计为需要补充血清，但在无血清条件下，RPMI 1640 也表现出可支持多种细胞系的生长。它还广泛用于细胞融合和杂交细胞的生长。
RPMI 1640 Medium was developed at Roswell Park Memorial Institute in 1966 by Moore and his co-workers. A modification of McCoy's 5A Medium, it was formulated to support lymphoblastoid cells in suspension culture, but it has since been shown to support a wide variety of cells that are anchorage dependent. Originally intended to be used with a serum supplement, RPMI 1640 has been shown to support several cell lines in the absence of serum. It has also been widely used in fusion protocols and in the growth of hybrid cells.
RPMI 1640 Medium was developed at Roswell Park Memorial Institute in 1966 by Moore and his co-workers. A modification of McCoy's 5A Medium, it was formulated to support lymphoblastoid cells in suspension culture, but it has since been shown to support a wide variety of cells that are anchorage dependent. Originally intended to be used with a serum supplement, RPMI 1640 has been shown to support several cell lines in the absence of serum. It has also been widely used in fusion protocols and in the growth of hybrid cells.
RPMI 1640 培养基由 Moore 及其同事于 1966 年在 Roswell Park Memorial Institute 开发。它是 McCoy′s 5A 培养基的改良型，在悬浮培养中可支持淋巴母细胞样细胞，但也证实可支持众多锚定依赖性细胞。最初设计为需要补充血清，但在无血清条件下，RPMI 1640 也表现出可支持多种细胞系的生长。它还广泛用于细胞融合和杂交细胞的生长。
RPMI 1640 培养基由 Moore 及其同事于 1966 年在 Roswell Park Memorial Institute 开发。它是 McCoy′s 5A 培养基的改良型，在悬浮培养中可支持淋巴母细胞样细胞，但也证实可支持众多锚定依赖性细胞。最初设计为需要补充血清，但在无血清条件下，RPMI 1640 也表现出可支持多种细胞系的生长。它还广泛用于细胞融合和杂交细胞的生长。
RPMI 1640 Medium was developed at Roswell Park Memorial Institute in 1966 by Moore and his co-workers. A modification of McCoy's 5A Medium, it was formulated to support lymphoblastoid cells in suspension culture, but it has since been shown to support a wide variety of cells that are anchorage dependent. Originally intended to be used with a serum supplement, RPMI 1640 has been shown to support several cell lines in the absence of serum. It has also been widely used in fusion protocols and in the growth of hybrid cells.
粤公网安备 44010602000434号
